Tirzepatide compared with semaglutide for the treatment of obesity

Why it matters. A head-to-head randomized comparison of two leading incretin agents helps rank obesity pharmacotherapy directly.

Provenance

Evidence grading reflects the portion of the source actually analyzed. Always confirm against the original before acting.

Post your interpretation for colleagues. Every post stays anchored to this source, no empty-box updates.